SCHEMBL3337610

SCHEMBL3337610

Cc1sc(NNC(=O)c2ccc(-c3ccccc3)cc2)nc1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.59
MEN1 O00255 8/20 0.59
GAA P10253 3/20 0.59
RAB9A P51151 2/20 0.59
NPC1 O15118 1/20 0.59
MAPT P10636 6/20 0.56
ALDH1A1 P00352 3/20 0.56
USP2 O75604 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
POLB P06746 2/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.50
RECQL P46063 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
THRB P10828 1/20 0.50
ALOX5 P09917 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PLTP P55058 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338327 0.82 KDM4E (0.61) KMT2AMEN1GAARAB9ANPC1
SCHEMBL3344292 0.82 KMT2A (0.51) KMT2AMEN1GAARAB9ANPC1
SCHEMBL3342093 0.78 MAPT (0.72) KMT2AMEN1GAARAB9ANPC1
SCHEMBL8552540 0.75 MAPT (0.56) KMT2AMEN1GAARAB9ANPC1
SCHEMBL4845147 0.74 MAPK1 (0.48) KMT2AMEN1RAB9AMAPTALDH1A1
SCHEMBL17107156 0.72 ALDH1A1 (0.79) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL2753568 0.72 ADORA3 (0.73) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL11779561 0.71 PTGS2 (0.66) KMT2AMEN1GAARAB9ANPC1
SCHEMBL4929277 0.70 MEN1 (0.77) KMT2AMEN1GAARAB9ANPC1
SCHEMBL9805952 0.70 POLB (1.00) KMT2AGAAMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US claimed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA KMT2A 3492/4885MEN1 1886/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.